TSX gains on big banks strength
CAMBRIDGE, MA—Timothy Keutzer, Chief Operating Officer of Spero Therapeutics , Inc. (NASDAQ:SPRO), recently executed a series of stock transactions, according to the latest SEC filings. On February 3, Keutzer acquired 266,139 shares of common stock, which are restricted stock units set to vest over four years starting in 2026. The transaction comes as InvestingPro data shows the company trading at $0.88 per share, with a market capitalization of approximately $48.4 million.
On February 5, Keutzer sold a total of 56,537 shares at a price of $0.78 per share. The sales, which amounted to a total of $44,097, were conducted to cover tax withholding obligations related to the vesting of previously granted restricted stock units. Following these transactions, Keutzer holds 741,439 shares of Spero Therapeutics. According to InvestingPro analysis, the company maintains strong financial health with a current ratio of 2.68 and more cash than debt on its balance sheet. While the stock has declined about 41% over the past year, two analysts have revised their earnings expectations upward for the upcoming period. Subscribers to InvestingPro can access 8 additional key insights about SPRO’s financial outlook and valuation metrics.
In other recent news, Spero Therapeutics has announced interim leadership changes amid a Securities and Exchange Commission (SEC) inquiry. Esther Rajavelu has been appointed as Interim President and CEO, with Frank Thomas stepping in as Chairman of the Board. The company has also reported progress on its Phase 3 PIVOT-PO trial for Tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, which has surpassed 60% enrollment and is expected to be fully enrolled by the second half of 2025.
H.C. Wainwright has reiterated its Buy rating on Spero Therapeutics, highlighting the company’s progress in its PIVOT-PO trial for tebipenem HBr. The firm expressed confidence in the timeline of the PIVOT-PO program, anticipating that top-line results could become available in early 2026.
In contrast, TD Cowen has downgraded its view on Spero Therapeutics from Buy to Hold due to uncertainties regarding the timing of upcoming catalysts. This follows the recent discontinuation of Spero’s Phase 2 program for its drug candidate aimed at treating nontuberculous mycobacterial infections. Despite this, Spero Therapeutics continues to work on other projects, including a Phase 2 trial for another of its drug candidates, known as ’206, targeting hospital-acquired and ventilator-associated bacterial pneumonia. These are among the recent developments concerning Spero Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.